• 1
    Margulies KB, Heublein DM, Perella MA, Burnett JC Jr. ANF-mediated renal cGMP generation in congestive heart failure. Am J Physiol 1991;260:F562F568.
  • 2
    Tsutamoto T, Kanamori T, Morigami N, et al. Possibility of downregulation of atrial natriuretic peptide receptor coupled to guanylate cyclase in peripheral vascular beds of patients with chronic severe heart failure. Circulation 1993;87:7075.
  • 3
    Chen HH, Schirger JA, Chau WL, et al. Renal response to acute neutral endopeptidase inhibition in mild and severe experimental heart failure. Circulation 1999;100:24432448.
  • 4
    Chen S, Sen S, Young D, et al. Protease corin expression and activity in failing hearts. Am J Physiol 2010;299:H1687H1692.
  • 5
    Meyer M, Zhang Q, Khurana K, et al. Negative functional effects of natriuretic peptides are attenuated in hypertrophic cardiac myocytes by reduced particulate guanylyl cyclase activity. J Cardiovasc Pharmacol 2007;49:100105.
  • 6
    Andreassi MG, Del Ry S, Palmieri C, et al. Up-regulation of ‘clearance’ receptors in patients with chronic heart failure: A possible explanation for the resistance to biological effects of cardiac natriuretic hormones. Eur J Heart Fail 2001;3:407414.
  • 7
    Boerrigter G, Costello-Boerrigter LC, Harty GJ, et al. Des-serine-proline brain natriuretic peptide 3-32 in cardiorenal regulation. Am J Physiol 2007;292:R897R901.
  • 8
    Brandt I, Lambeir A-M, Ketelslegers J-M, et al. Dipeptidyl-peptidase IV converts intact B-type natriuretic peptide into its des-SerPro form. Clin Chem 2006;52:8287.
  • 9
    Shimizu H, Masuta K, Aono K, et al. Molecular forms of human brain natriuretic peptide in plasma. Clin Chim Acta 2002;316:129135.
  • 10
    Lam CSP, Burnett JC Jr, Costello-Boerrigter L, et al. Alternate circulating pro-B-type natriuretic peptide and B-type natriuretic peptide forms in the general population. J Am Coll Cardiol 2007;49:11931202.
  • 11
    Dukes-McEwan J, Borgarelli M, Tidholm A, et al. Proposed guidelines for the diagnosis of canine idiopathic dilated cardiomyopathy. J Vet Cardiol 2003;5:719.
  • 12
    Fox PR, Sisson D, Moïse NS. Appendix A recommendations for diagnosis of heart disease and treatment of heart failure in small animals. In: PR Fox, DD Sisson, NS Moise, eds. Textbook of Canine and Feline Cardiology Principles and Clinical Practice, 2nd ed. Philadelphia, PA: WB Saunders Company; 1999:883901.
  • 13
    Scharpé S, De Meester I, Vanhoof G, et al. Assay of dipeptidyl peptidase IV in serum by fluorometry of 4-methoxy-2-naphthylamine. Clin Chem 1988;34:22992301.
  • 14
    Matheeussen V, Baerts L, De Meyer G, et al. Expression and spatial heterogeneity of dipeptidyl peptidases in endothelial cells of conduct vessels and capillaries. Biol Chem 2011;392:189198.
  • 15
    SAS Institute Inc. SAS/STAT® User's Guide, Version 6, 4th ed., Volume 2. Cary, NC: SAS Institute Inc; 1989:846.
  • 16
    Goetze JP. Biochemistry of pro-B-type natriuretic peptide-derived peptides: The endocrine heart revisited. Clin Chem 2004;50:15031510.
  • 17
    Smith MW, Espiner EA, Yandle TG, et al. Delayed metabolism of human brain natriuretic peptide reflects resistance to neutral endopeptidase. J Endocrinol 2000;167:239246.
  • 18
    Lambeir AM, Durinx C, Scharpé S, De Meester I. Dipeptidyl peptidase IV from bench to bedside: An update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci 2003;40:209294.
  • 19
    Jarmolowska B, Bielikowicz K, Iwan M, et al. Serum activity of dipeptidyl peptidase IV (DPPIV; EC3.4.14.5) in breast–fed infants with symptoms of allergy. Peptides 2007;28:678682.
  • 20
    De Chiara L, Rodriguez-Pineiro AM, Cordero OJ, et al. Soluble CD26 levels and its association to epidemiologic parameters in a sample. Dis Markers 2009;27:311316.
  • 21
    Carr RD, Larsen MO, Jelic K, et al. Secretion and dipeptidyl peptidase-4-mediated metabolism of incretin hormones after a mixed meal or glucose ingestion in obese compared to lean, nondiabetic men. J Clin Endocrinol Metab 2010;95:872878.
  • 22
    McKillop AM, Duffy NA, Lindsay JR, et al. Decreased dipeptidyl peptidase-IV activity and glucagon-like peptide-1(7-36) amide degradation in type 2 diabetic subjects. Diabetes Res Clin Pract 2008;79:7985.
  • 23
    Papies B, Frille J, Günther KH, Wagenknecht C. Isoenzyme (lactate dehydrogenase, aspartate aminotransferase) and dipeptidyl peptidase IV activity changes in blood plasma likely indicative of organ involvement due to arterial hypertension. Cor Vasa 1991;33:218226.
  • 24
    Sauvé M, Ban K, Momen MA, et al. Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice. Diabetes 2010;59:10631073.